Form 4: Amgen SVP & CCO Nancy Grygiel Acquires 2,010 Shares

Amgen's Senior Vice President and Chief Compliance Officer, Nancy A. Grygiel, reported the acquisition of 2,010 shares of common stock.

Summary

• Nancy A. Grygiel, Amgen Inc.'s Senior Vice President and Chief Compliance Officer, acquired 2,010 shares of Amgen common stock.
• The transaction occurred on March 3, 2026, with a reported price of $0 per share, indicating a grant or award rather than a cash purchase.
• Following this acquisition, Grygiel directly beneficially owns 9,249 shares, which include 110 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
• These Dividend Equivalents are credited to unvested Restricted Stock Units (RSUs) and are paid out in shares of common stock on a one-to-one basis upon vesting.
• Additionally, Grygiel indirectly owns 105.465 shares through the company's 401(k) Plan, representing interests in the Company's stock fund.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an executive's increased equity stake, even through a grant, generally indicates alignment with shareholder interests and confidence in the company's performance.

Positives

• An executive acquiring additional shares, even through a grant, generally signals alignment of interests with shareholders and confidence in the company's future.
• The inclusion of Dividend Equivalents (DEs) on unvested RSUs provides additional value to the executive's equity holdings, enhancing long-term incentive.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions, are often viewed by the market as a positive signal, indicating management's confidence in the company's future prospects. In the pharmaceutical and biotechnology industry, executive equity holdings are a common component of compensation, aligning leadership incentives with long-term shareholder value.

Comparison to Industry Standards

• Executive equity grants are a standard component of compensation packages across the pharmaceutical and biotech sectors, similar to practices at companies like Pfizer, Merck, and Johnson & Johnson.
• The use of Dividend Equivalents (DEs) tied to unvested RSUs is a common mechanism in equity incentive plans to ensure executives benefit from dividends even before full vesting, aligning with best practices for long-term retention and performance incentives.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders due to higher equity ownership.
• Employees: Reflects standard executive compensation practices within the company.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a senior executive, which is an expected part of compensation. While it signals executive alignment, it does not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific transaction.

Keywords

Amgen, AMGN, Insider Trading, Form 4, Stock Acquisition, Executive Compensation, Nancy Grygiel, SVP & CCO, Equity Incentive Plan, Dividend Equivalents